%0 Journal Article
%T British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab.
%A Dobson R
%A Ghosh AK
%A Ky B
%A Marwick T
%A Stout M
%A Harkness A
%A Steeds R
%A Robinson S
%A Oxborough D
%A Adlam D
%A Stanway S
%A Rana B
%A Ingram T
%A Ring L
%A Rosen S
%A Plummer C
%A Manisty C
%A Harbinson M
%A Sharma V
%A Pearce K
%A Lyon AR
%A Augustine DX
%J Echo Res Pract
%V 8
%N 1
%D 03 2021 31
%M 34106116
暂无%R 10.1530/ERP-21-0001
%X The subspecialty of cardio-oncology aims to reduce cardiovascular morbidity and mortality in patients with cancer or following cancer treatment. Cancer therapy can lead to a variety of cardiovascular complications, including left ventricular systolic dysfunction, pericardial disease, and valvular heart disease. Echocardiography is a key diagnostic imaging tool in the diagnosis and surveillance for many of these complications. The baseline assessment and subsequent surveillance of patients undergoing treatment with anthracyclines and/or human epidermal growth factor (EGF) receptor (HER) 2-positive targeted treatment (e.g. trastuzumab and pertuzumab) form a significant proportion of cardio-oncology patients undergoing echocardiography. This guideline from the British Society of Echocardiography and British Cardio-Oncology Society outlines a protocol for baseline and surveillance echocardiography of patients undergoing treatment with anthracyclines and/or trastuzumab. The methodology for acquisition of images and the advantages and disadvantages of techniques are discussed. Echocardiographic definitions for considering cancer therapeutics-related cardiac dysfunction are also presented.